Episode 107- Kevin Marks - CEO Delphia Therapeutics

Today’s guest is Kevin Marks, a biotech entrepreneur and the founder and CEO of Delphia Therapeutics. Kevin has spent his career at the forefront of cancer drug discovery, working across research, strategy, and company building with a singular focus on translating breakthrough science into meaningful medicines for patients. Before founding Delphia, he built deep experience in oncology and precision medicine, helping advance novel therapeutic programs and navigating the complex path from early discovery to clinical development. At Delphia Therapeutics, Kevin is leading the development of a new approach to precision oncology known as activation lethality—an emerging strategy designed to uncover previously untapped cancer vulnerabilities and deliver more targeted, effective treatments.

With a background that blends rigorous science, entrepreneurial leadership, and a patient-first mindset, Kevin brings a thoughtful perspective on the future of cancer therapy, innovation in biotech, and what it truly takes to build a science-driven company from the ground up. We’re excited to have him with us today.